Sulfasalazine Market Poised to Witness High Growth Due to Increasing Geriatric Population
The global sulfasalazine market is estimated to be valued at US$ 2.32 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
SWOT Analysis
Strength: Sulfasalazine is a highly effective treatment for rheumatoid arthritis and inflammatory bowel diseases like ulcerative colitis. It is prescribed generically and is very affordable compared to newer biologic drugs. Sulfasalazine has a well-established safety profile due to its long history of clinical use.
Weakness: Sulfasalazine can cause side effects like nausea, vomiting, diarrhea and headaches in some patients. Long term use may occasionally lead to serious adverse reactions like hepatitis and neurological problems. The drug requires regular monitoring of blood counts and liver function during therapy.
Opportunity: The market offers scope to develop new formulations and delivery systems of sulfasalazine that are better tolerated. Combination therapies including sulfasalazine and newer drugs can be explored to achieve superior treatment outcomes. Expansion into new therapeutic areas like psoriatic arthritis presents commercial opportunities.
Threats: Emergence of safer and highly effective biologic drugs is reducing the use of sulfasalazine as a first line therapy. Strict regulations and compliance requirements add to production costs and pricing pressures in the market. Patent expiries of major sulfasalazine brands enable growth of low-cost generics.
Key Takeaways
The Global Sulfasalazine Market Growth is expected to witness high.
Regional analysis: The Asia Pacific region dominates the global sulfasalazine market currently due to high disease burden, growing medical infrastructure and presence of major generic players. China accounts for over 30% of the global sulfasalazine demand backed by its huge population and increasing healthcare spending. Western European countries like Germany and United Kingdom also have significantmarketsharesdue to heavy usage of sulfasalazine in inflammatory bowel disease therapy.
Key players operating in the sulfasalazine market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Major companies are focusing on generics production and new regional expansions to strengthen their positions.
Explore more information on this topic, Please visit -
https://www.trendingwebwire.com/sulfasalazine-market-size-and-demand-analysis/
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian